Zinc Sulfate

Zinc Sulfate may be found in some form under the following brand names:

• Clear Eyes ACR

• Clear Eyes Complete

• Clear Eyes Cooling Comfort

• Clear Eyes Tears and Itchy Eye Relief

• Concept OB

• Eldertonic

• Ellis Tonic

• Eye-Sed

• Ferrocite Plus

• Hemocyte Plus

• M.t.e.-5

• M.t.e.-6

• M.t.e.-7

• Mar-Zinc

• MulTE-PAK-5

• Multitrace-4

• Multitrace-5

• Multitrace-5 Concentrate

• Neotrace-4

• Orazinc

• P.t.e.-5

• Pedtrace-4

• RightStep

• Tandem OB

• Tandem Plus

• VasoClear A

• Verazinc

• Visine AC

• Visine Totality

• Zinca-pak

• Zincate

• Zincfrin

Zinc Sulfate is available in the following forms:

• Extended Release Tablet
• Injectable Solution
• Lozenge
• Ophthalmic Gel
• Ophthalmic Solution
• Oral Capsule
• Oral Solution
• Oral Tablet
• Rectal Suppository

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, severe vomiting, dehydration, and restlessness.

Injection: Do not administer undiluted into peripheral vein

Refer to adult dosing.

May be taken with food if GI upset occurs.

Capsule: Store at 15°C to 30°C (59°F to 86°F).

Tablet (Orazinc®): Store at 13°C to 24°C (55°F to 76°F).

Injection: Prior to use, store at room temperature of 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Disease-related concerns:

• Renal impairment: Use with caution in patients with renal impairment.

Concurrent drug therapy issues:

• Copper: IV administration of zinc without copper may cause a decrease in copper serum concentrations.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer’s labeling.

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.